All Allergan articles
-
BusinessPharmaceuticals roundup 2019
Under the shadow of political turmoil and major lawsuits, the industry returned to its strengths – making new drugs, and finding new ways to do it better
-
BusinessAbbVie to acquire Allergan in multibillion-dollar merger
Takeover deal will create world’s fifth-largest pharma company
-
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessUS probes opioid manufacturers
Attorneys general from 41 states will investigate companies over alleged fraudulent marketing and distribution of painkillers
-
BusinessAllergan sidesteps patent review with tribal deal
Native Americans agree to use sovereign immunity to protect intellectual property from double challenge
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessIndia’s Intas bags UK and Irish generics
Teva sheds former Actavis business to satisfy competition requirements of its Allergan generics takeover
-
BusinessAcquisition spree moves Allergan towards innovative drugs
Company acquires five companies in six weeks across three disease areas
-
BusinessUS government sued over merger crackdown
Business groups challenge Obama’s steps to limit tax inversions
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
Business
Teva sells off products in preparation for Allergan merger
Generics deals with Impax, Dr Reddy’s and Sagent aimed at satisfying competition authorities
-
BusinessUS treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
-
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Allergan steps away from generics with sale to Teva
$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs